GlassScriptPhysician profile
Charles E Lubash
NPI 1063554525
$1,290.90
in general payments reported to CMS, 2019-2025
34 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.38 · 2022: $165 · 2023: $354 · 2024: $315 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,068.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $146.79 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.81 | 2024-2025 | |
| Janssen Biotech, INC. | $77.81 | 2022-2025 | Erleada, Talvey, Darzalex |
| Genentech USA, INC. | $69.03 | 2023-2025 | Venclexta, Tecentriq, Rozlytrek |
| E.R. Squibb & Sons, L.L.C. | $67.06 | 2023-2025 | Opdivo, Augtyro, Opdualag |
| Astrazeneca Pharmaceuticals LP | $66.78 | 2022-2025 | Enhertu |
| Daiichi Sankyo INC. | $54.00 | 2021-2025 | Enhertu |
| Celgene Corporation | $47.97 | 2021-2022 | |
| Sobi, INC | $45.37 | 2022-2024 | |
| Lilly USA, LLC | $43.48 | 2023 | Jaypirca, Verzenio |
| Glaxosmithkline, LLC. | $42.00 | 2023-2024 | Ojjaara |
| Genzyme Corporation | $40.66 | 2023 | |
| Seagen INC. | $38.18 | 2023 | Adcetris |
| Rigel Pharmaceuticals, INC. | $36.30 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Incyte Corporation | $34.87 | 2025 | Monjuvi, Jakafi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $29.30 | 2024 | Brukinsa |
| Array Biopharma INC | $28.23 | 2022-2025 | Braftovi, Mektovi |
| Jazz Pharmaceuticals INC. | $27.89 | 2022 | |
| Astellas Pharma US INC | $27.75 | 2024 | Padcev |
| Amneal Pharmaceuticals LLC | $24.66 | 2025 | Alymsys |
| Alexion Pharmaceuticals, INC. | $24.52 | 2023 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $22.32 | 2025 | |
| Adaptive Biotechnologies Corporation | $21.67 | 2023 | Clonoseq |
| Pharmaessentia USA Corporation | $20.96 | 2025 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $20.05 | 2023 | Fruzaqla |
| Amgen INC. | $18.93 | 2024 | Kyprolis, Neulasta, Vectibix |
| Taiho Oncology, INC. | $18.12 | 2023 | |
| Merck Sharp & Dohme LLC | $17.85 | 2022 | |
| Mirati Therapeutics, INC. | $17.82 | 2024 | Krazati |
| Abbvie INC. | $15.76 | 2024 | |
| Puma Biotechnology, INC. | $15.19 | 2023 | |
| Emd Serono, INC. | $14.61 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.23 | 2022 | |
| Gilead Sciences, INC. | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Lubash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.